We have previously reported that two highly conserved amino acids in the C-terminal domain of rat insulin-like growth factor-binding protein ( 
The actions of insulin-like growth factors (IGFs) 1 are mediated by binding to and activating type 1 IGF receptors, which are found on the surface of most cell types. In turn, IGFs are regulated by a family of six IGF-binding proteins (IGFBPs) that form high affinity complexes with both IGF-I and IGF-II (reviewed in Ref. 2) . Because the affinity constants of the IGFBPs are between 2-and 50-fold greater for binding IGFs than that of the IGF type 1 receptor, it is thought that the IGFBPs are able to regulate the bioavailability of IGFs in different biological fluids.
IGFBPs are proteins of 216 -289 residues, and all share a common protein structure that can be conceptually divided up into three domains, where a domain may be defined as a region of a protein that can fold into a tertiary structure independent of neighboring sequences (2) (Fig. 1 ). There is a particularly high degree of conservation in the N-and C-terminal domains, which contain 12 and 6 cysteine residues, respectively, in IGFBPs 1-6 of all species sequenced so far. A nonconserved region separating the N-and C-terminal domains contains most of the sites for proteolysis and post-translational modifications. Both the N-and C-terminal cysteine-rich domains of IGFBPs are believed to participate in IGF binding. This is supported by work where fragments from the N-terminal cysteine-rich domains of IGFBP-1 (3), IGFBP-3 (4), IG-FBP-4 (5), and IGFBP-5 (6, 7) and the C-terminal cysteine-rich domains of IGFBP-2 (8, 9) and IGFBP-3 (10) were generated and shown to possess residual IGF binding activity. More recently, several groups have reported biosensor analysis of Nand C-terminal fragments of bovine IGFBP-2 and human IG-FBP-3 (11) (12) (13) , and all of these studies indicated that there were major IGF-binding sites in both the N-and C-terminal domains.
Work from several laboratories has already identified the specific amino acids in the N-terminal domain of the IGFBP molecule that contribute to IGF binding. Initially it was observed that Tyr 60 was protected against iodination upon binding of bovine IGFBP-2 to IGF-II (14) , and subsequently, the same group demonstrated that substitution of this amino acid leads to reduced affinities for IGF-I and -II (15) . In addition, NMR was carried out on a bacterially expressed N-terminal fragment of IGFBP-5 (residues 40 -92), and this clearly demonstrated that a major IGF-binding domain comprises Val 49 , Tyr 50 (equivalent to Tyr 60 in IGFBP-2), Pro 62 , and Lys 68 -Leu 75 , where the conserved Leu and Val residues localize in a hydrophobic patch on the surface of the IGFBP-5 protein (7). Subsequently, it was shown that substituting specific hydrophobic residues in this region of IGFBP-5 resulted in an ϳ1000-fold reduction in affinity for IGF-I, as measured by solution phase ligand binding assays (1) . However, there remains a possibility that the effects of these mutations are nonspecific because they may have caused a gross alteration in protein structure, despite the fact that they did not involve the highly conserved cysteine residues.
The NMR study described above also found that the Nterminal fragments of IGFBP-5 had a 10 -200-fold lower affin-ity for IGFs than the full-length protein (7) , which agrees well with the reported reduced affinities of other C-terminally truncated fragments of IGFBP-3 (16) and IGFBP-5 (6). This indicated that other residues at the C terminus of the IGFBP proteins must be required in the additional stabilization of IGF complex formation that leads to high affinity binding. Less attention has focused on identifying the C-terminal residues in IGFBPs that are involved in IGF interaction. However, a strong clue as to where some or all of these important residues may lie came from a deletion analysis of the C terminus of bovine IGFBP-2, which identified a critical region between amino acids 222 and 236 of IGFBP-2 involved in binding IGFs (17) . This region of bovine IGFBP-2 corresponds to amino acid sequences in both IGFBP-5 and -3, which are rich in basic residues (201-218 in IGFBP-5). Although several of these basic amino acids have been shown to play a critical role in IGFBP-5 binding to both heparin and the extracellular matrix (18 -20) , it has also been demonstrated that extensive mutagenesis of the basic amino acids alone had no effect on IGF-I binding (21, 22) .
Nevertheless, alignment of amino acid sequences for all six binding proteins from several species reveals that there are two completely conserved nonbasic amino acids (Gly  203 and Gln   209 in rat IGFBP-5) within this region (Fig. 1) , and this conservation suggests an important function for these amino acids. We have shown previously that mutation of either Gly 203 or Gln 209 results in a significant reduction in affinity for binding to IGF-I (7-and 6-fold, respectively) but has no effect on heparin binding (22, 23) . This clearly demonstrates that there is overlap of IGF and heparin-binding sites in the C-terminal domain of IGFBP-5.
In the present study, we investigate whether there is a cumulative effect on the ability of IGFBP-5 to bind to IGF-I (or heparin) when both Gly 203 and Gln 209 are mutated simultaneously (G203A/Q209A; C-Term), and we also extend these mutations to the corresponding residues in IGFBP-2 (G211A/ Q217A; C-Term 2) to determine whether this reflects a conserved IGF-binding site in IGFBPs. In addition, to ascertain the relative contribution of the N-and C-terminal domains of IGFBP-5 in binding IGF-I, we have recreated the mutations described by Imai et al. (1) in the N terminus (K68N/P69Q/ L70Q/L73Q/L74Q; N-Term) and compared IGF-I binding of C-Term, N-Term, and a combined mutant, NϩC-Term, by ligand blotting, solution phase IGF binding assays, and biosensor real time analysis of binding kinetics. Furthermore, because it was not previously reported whether the mutations in the IGFBP-5 C terminus (22, 23) or N terminus (1) led to a conformational change in the protein structure, we have carried out CD analysis on both C-Term and N-Term to establish whether these mutations are specific for IGF binding. The implications of these findings for IGFBP-5 interaction with IGFs and heparin are discussed.
MATERIALS AND METHODS
Site-directed Mutagenesis-The full-length cDNAs for rat IGFBP-5 and -2 in pGEM-7zf (Promega, Madison, WI), containing both initiator and signal peptide, was kindly provided by Dr. S. Guenette (John Wayne Cancer Institute, Los Angeles, CA). Site-directed mutagenesis was carried out using the QuikChange TM system (Stratagene, La Jolla, CA), following the protocol provided by the manufacturer. The rat and mouse protein sequence of IGFBP-5 only differs by a single amino acid at position 188 (Asp and Glu, respectively). Site-directed mutagenesis was employed to convert wt rat to wt mouse sequences (D188E) using the oligonucleotides: 5Ј-GAC AGG AAT CTG AAC AAG GCC CCT GCC-3Ј and 5Ј-GGC AGG GGC CTT GTT CAG ATT CCT GTC-3Ј. The oligonucleotide used to make Q209A was described previously (21) . Q209A was used as a template to make C-Term (G203A/Q209A) using the oligonucleotides 5Ј-AAC TGT GAC CGC AAA GCT TTC TAC AAG AGA AAG-3Ј and 5Ј-CTT TCT CTT GTA GAA AGC TTT GCG GTC ACA GTT-3Ј. N-Term (K68N/P69Q/L70Q/L73Q/L74Q) was made using the oligonucleotides 5Ј-GGA TGA GGA GAA CCA GCA GCA CGC CCA GCA GCA CGG CCG CGG-3Ј and 5Ј-CCG CGG CCG TGC TGC TGG GCG TGC TGC TGG TTC TCC TCA TCC-3Ј. The NϩC-Term composite mutant was made by using the unique SacII restriction endonuclease site in the IGFBP-5 cDNA sequence to cut and ligate N-Term and C-Term sequences together. The wt rat IGFBP-2 cDNA was mutated to make C-Term 2 (G211A/Q217A) using the oligonucleotides 5Ј-AAC TGT GAC AAG CAT GCT CTG TAC AAC CTC AAA GCT-3Ј and 5Ј-CAG AGA CAT CTT GCA AGC TTT GAG GTT GTA CAG AGC-3Ј. Our previously reported "heparin minus" (HepϪ) mutant is defective in its ability to bind to heparin (22) . All of the oligonucleotides were synthesized by MWG BioTech (Milton Keynes, UK). Following site-directed mutagenesis, automated DNA sequencing (MWG BioTech) was carried out on all clones to confirm that the correct mutations had been made.
Bacterial Expression-Expression of recombinant IGFBP-5 proteins was carried out using conditions identical to those described previously (24) . Briefly, mouse wt IGFBP-5 and the various IGFBP-5 mutants were cloned without the signal peptide-encoding sequence into the pGEX 6P-1 vector (Amersham Biosciences), so that the proteins would have an N-terminal glutathione S-transferase (GST) tag. The proteins were expressed in the Origami B (DE3) pLysS strain of Escherichia coli (Novagen, Madison, WI), and following cell lysis the GST-IGFBP-5 fusion proteins were extracted from the soluble fraction only and subsequently subjected to two rounds of purification. The cell lysates were loaded onto glutathione-Sepharose columns (Amersham Biosciences), and the purified IGFBP proteins were then eluted following removal of the GST tag with PreScission protease (Amersham Biosciences). Subsequently, the untagged IGFBP proteins were purified on IGF-I affinity columns and quantified as described previously (20) . Commercial mouse IGFBP-5 expressed in the mouse myeloma cell line NSO was purchased from R&D Systems, Inc. (Minneapolis, MN). Rat wt IGFBP-2 and C-Term 2 were expressed untagged using the pET-15b vector (Novagen) in Origami B cells, using the same methodology as that used for the IGFBP-5 proteins, except the cell lysate supernatant was used for subsequent analyses.
CD Spectroscopy and Fluorescence-To compare the secondary structures of wt IGFBP-5, C-Term, and N-Term proteins, CD spectropolarimetry data were recorded using a JASCO J-600 spectropolarimeter in cells with path lengths of 0.02 cm (far-UV) using protein concentrations of 0.5 mg/ml for both wild type and mutant IGFBP-5 samples (time constant, 2 s; scan speed, 10 nm/min). The secondary structure contents of wild type, C-Term, and N-Term mutants were estimated using the CONTIN procedure of Provencher and Glöckner (25) and the SELCON procedure of Sreerama and Woody (26) . Secondary structure estimates were obtained using data values down to 190 nm in both the wild type and N-Term proteins. In the case of the C-term mutant, the signal to noise ratio was not favorable below 197 nm, thus precluding the use of data below this wavelength. Fluorescence spectra were recorded using a Perkin Elmer LS50B fluorimeter in 1-cm-path length cells using protein concentration of 0.1 mg/ml for both wild type and mutant samples; (excitation, 290 nm; slits of 5-nm band pass).
IGF-I Ligand Blotting and Western
Immunoblotting-The proteins were electrophoresed on 12% acrylamide SDS-PAGE gels under nonreducing conditions and subsequently transferred to nitrocellulose membranes. The ligand blots were performed according to the method described previously (27) , using IGF-I (GroPep Limited, Adelaide, Australia) radiolabeled to a specific activity of ϳ100 Ci/g. Western blots with either an "in-house" sheep anti-rat IGFBP-5 antiserum or a commercial rabbit anti-bovine IGFBP-2 antibody (Upstate Biotechnology, Inc., Lake Placid, NY) were performed as described previously (23) and were used to monitor protein loading during ligand and heparin blotting experiments. The method used for heparin ligand blotting was also described previously (22) .
Solution Phase IGF Binding Assay-Binding affinities for IGF-I were assayed in solution by the method described previously by Conover et al. (28) . The assays were performed using the PreScission protease eluate fractions obtained after expression of wt IGFBP-5 and the C-Term mutant and the supernatant bacterial lysates containing recombinant wt IGFBP-2 and the C-Term 2 mutant. The optimal amount of each protein preparation was calculated following initial saturation binding assays containing 25,000 -30,000 dpm (15-18 fmol) [ Biosensor Analysis-Biosensor studies were performed using the Biacore 3000 instrument. Human IGF-I (10 g/ml in 10 mM sodium acetate, pH 5) was immobilized into flow cell 2 of three separate CM5 biosensor chips at ligand densities of 50, 100, and 200 response units. To provide a control binding surface, insulin was immobilized in flow cell 1 of the three biosensor chips at the same level of ligand density. Both IGF-I and insulin were immobilized using amine-coupling chemistry according to protocols provided by the manufacturer. For kinetic studies, purified proteins were injected at five different concentrations and at a flow rate of 30 l/min in 10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20. All of the experiments were performed at ambient temperature. The protein concentrations were as follows: commercial mouse IGFBP-5 and wt mouse IGFBP-5 (in-house): 1.56, 3.125, 6.25, 12.5, and 25 nM; C-Term, 3.125, 6.25, 12.5, 25, and 50 nM; and N-Term and NϩC-Term, 25, 50, 100, 200, and 400 nM. The association and dissociation phases of the binding curves were 3 and 15 min, respectively, for the commercial protein and 5 and 15 min, respectively, for all others. Following binding the surface of the chip was regenerated by two 30-s pulses of 50 mM NaOH, 1 M NaCl. Protein samples and a buffer blank were injected in duplicate and in random order using each of the three biosensor chips. The data were analyzed assuming a 1:1 stoichiometry of interaction between IGF-I and IG-FBP-5 using the Langmuir model provided in the BiaEvaluation 3.1 software and employing the global data analysis option.
RESULTS
N-terminal sequence analysis of the recombinant wt IG-FBP-5 protein showed the expected sequence (GPLGSLGS-FVHCEPCDDEK) derived from pGEX 6P-1 and the mature IGFBP-5 sequence minus signal peptide, indicating that there had been proper processing by PreScission protease. 2 It can be seen from the CD results ( Fig. 2A) apparently significant differences in amplitude, the secondary structure estimates (given in Table I ) are broadly similar, exhibiting a strong negative band with a minimum close to 200 nm in each case. Secondary structure estimates of these spectra indicate a low percentage of ␣-helix and a greater proportion of ␤-sheet and ␤-turns for each protein. The fluorescence emission spectra (Fig. 2B) show that wt IGFBP-5, C-Term, and N-Term have very similar emission maxima (ϳ345 nm) with considerable differences in intensity. In view of the fact that intensity depends on the relative magnitudes of the rates of various processes that lead to the decay of the excited state, the emission maximum is generally regarded as a more reliable indicator of the polarity of the Trp environments in a protein (29) . On this basis, the solvent exposure of the Trp side chains is very similar in the three proteins, indicating that little or no overall change in tertiary structure has occurred.
Following on from this, we compared [ 125 I]IGF-I binding of the mutant IGFBP-5 proteins, N-Term, C-Term, and NϩC-Term, to that of the wt protein using ligand blotting (Fig. 3,  upper panel) . The same filter was also subject to Western analysis with the appropriate antiserum to verify equivalent protein loading (Fig. 3, lower panel) . Although all three mutant proteins displayed reduced IGF-I binding, we note that relative to wt IGFBP-5, the greatest effect on IGF-I binding was with N-Term and NϩC-Term, which display no apparent binding on ligand blots (Fig. 3) .
We also examined the affinity of these mutant proteins in a solution phase analysis of the IGF-I-IGFBP interaction (Fig. 4) . As a further confirmation of the IGF binding properties of these IGFBP-5 mutant proteins, we undertook a biosensor analysis of binding kinetics of the proteins to IGF-I immobilized to a biosensor surface (Fig. 5 ). In agreement with the solution phase data above, the commercial and in-house wt IGFBP-5 proteins had almost exactly the same K D values, with 0.22 and 0.21 nM, respectively. However, the K D values for N-Term, C-Term, and NϩC-Term were 12.5, 2.1, and 25.9 nM, respectively. For N-Term and C-Term this demonstrates 60-and 10-fold reductions in affinity for binding IGF-I compared with the wt protein and a cumulative effect of the NϩC-Term mutant, which displays a 126-fold reduction in binding. This type of analysis also gives details of on and off rate kinetic constants, from which equilibrium constants can be derived (Table II) . Closer inspection of the biosensor data revealed that although the N-and C-Term mutants displayed similar changes to their K off or rate of dissociation values, the overall larger reduction in IGF-I affinity observed for N-Term was primarily due to a substantially slower K on or rate of association compared with C-Term. Finally, the highest reduction in IGF-I affinity observed for the NϩC-Term mutant was largely the result of a cumulative effect on its K off , which was approximately twice as fast as that of either N-or C-Term. We also note that the absolute K D values for wt IGFBP-5 and C-Term varied by up to 2-fold between biosensor and solution phase assays and that C-Term displayed a greater reduction in binding relative to the wt protein in the latter system (30-fold versus 10-fold).
Because Gly 203 and Gln 209 lie within the heparin-binding site between amino acids 201 and 218 in the C-terminal domain of IGFBP-5, experiments were also carried out to investigate I-human IGF-I and measurement of bound ligand by the method described previously (27) . This experiment was repeated three times with similar results in each instance.
the heparin binding properties of the C-Term mutant. Using a heparin blotting methodology we have previously reported that wt IGFBP-5 and the two single mutants, G203A and Q209A, bind to heparin in this system, whereas the HepϪ mutant, which contains mutations at four basic residues in this region (R201L, K202E, K206Q, and R214A) binds heparin very poorly (22) . We have now used this system to compare heparin binding between wt IGFBP-5, C-Term (G203A/Q209A combined) and HepϪ (Fig. 6, upper panel) . Although wt IGFBP-5 and C-Term display comparable binding to heparin in this system, there is no evidence of binding for HepϪ. As with the IGF ligand blotting, corresponding Western blots were carried out to verify equivalent protein loading (Fig. 6, lower panel) . Therefore, the residues Gly 203 IGFBPs from all species sequenced to date, we investigated whether these residues were also involved in IGF-I binding in a different IGFBP species, IGFBP-2. Ligand Western analysis and solution phase IGF binding assays were carried out on wt IGFBP-2 and the C-Term 2 mutant, which contains the corresponding amino acid substitutions (G211A/Q217A) in the rat IGFBP-2 sequence (Fig. 7) . IGF ligand blotting demonstrated that there was a very significant reduction in C-Term 2 binding to [
125 I]IGF-I relative to wt IGFBP-2, where only a faint band was detectable for C-Term 2 (Fig. 7A, upper panel) . We note that Western blot analysis of the same filter using an anti-IGFBP-2 antiserum demonstrated equivalent protein loading of wt IGFBP-2 and C-Term 2 (Fig.  7A, lower panel) . Further support of this conclusion comes from the observation that the solution phase binding curves also demonstrate compromised IGF-I binding for C-Term 2 relative to the wt protein (Fig. 7B) . Scatchard analysis derived from binding curves for wt IGFBP-2 and C-Term 2 (K D values of 0.14 and 0.61 nM, respectively) indicated that C-Term 2 had a 4.5-fold lower affinity than the wt protein for binding IGF-I. Taken together, these results clearly demonstrate that Gly 211 and Gln 217 in the IGFBP-2 sequence are involved in binding to IGF-I.
DISCUSSION
At the outset, we considered it essential to establish whether the effects of our amino acid substitutions in the IGFBP-5 sequence on IGF-I binding were specific or were simply the effect of a gross conformational change in protein structure. CD spectra were obtained to compare the secondary structures of wt IGFBP-5, C-Term, and N-Term, and it was observed that the overall shapes of the spectra were similar for all three proteins. Interestingly, similar CD spectra have also been shown for other proteins, including oxidized ribonuclease and a subclass of all-␤ proteins (termed ␤-II proteins) such as ␣-chymotrypsin, elastase, and soy bean trypsin inhibitor protein. X-ray diffraction data have shown that these ␤-sheet proteins are either highly distorted or made up of short irregular ␤ strands (30, 31) , and this could also hold true for IGFBP-5. The fluorescence spectra show that wt IGFBP-5, C-Term, and NTerm have very similar emission maxima, which indicates that the orientation of the Trp side chains is very similar in the three proteins. However, subtle changes in the microenvironments of the these side chains could effect the efficiency of quenching by moieties such as disulfide bonds, and it is possible that this could account for the significant differences observed in the intensity of fluorescence spectra for the three proteins. Nevertheless, these spectra would argue that little or no overall change in tertiary structure has occurred between the wt protein and the two mutants. Therefore, taken together our structural analyses confirm that the amino acid substitutions that we have made in both N-Term and C-Term have not led to gross changes in protein structure.
Bearing this in mind, our experiments confirm the previous work of Imai et al. (1) , which showed that these N-Term mutations led to the disruption of a major IGF-I-binding site in IGFBP-5, because both groups report very large decreases in binding with the same amino acid substitutions. However, although we could not detect any binding to N-Term and NϩC-Term using solution phase IGF binding assays, Imai et al. (1) reported an ϳ1000-fold reduction in IGF-I binding for their corresponding N-Term mutant. This apparent discrepancy is likely to be due to minor variations in the solution phase IGF binding protocols employed by the two labs. Another difference is that our analyses were with bacterially expressed proteins, whereas Imai et al. (1) expressed their recombinant proteins in Chinese hamster ovary cells (1) . However, we also demonstrate that a commercial mouse wt IGFBP-5 protein, which was expressed in mammalian cells and is therefore likely to be properly post-translationally modified (phosphorylated and glyco- Ligand blotting was performed as described previously (22) . As for the IGF-ligand blots described in Fig. 3 I-human IGF-I. Bound ligand was then measured by the method described previously (27) . Control assays were run simultaneously with cleared lysates from E. coli transformed using empty vector (data not shown), and these data were subtracted from the binding curves. This experiment was repeated three times with the same results in each instance. sylated), has almost exactly the same affinity for binding IGF-I in solution phase assays and biosensor analysis as our bacterially expressed wt protein. This is supported by other work where it was shown that mutagenesis to remove the glycosylation sites or expression in a prokaryotic nonglycosylating system had no effect on the binding of IGFBP-3 to IGF-I (32, 33) . Therefore, post-translational modifications of either IGFBP-5 or -3 do not appear to affect IGF-I binding.
In addition to confirming that there is a major IGF-binding site in the N-terminal domain of IGFBP-5, the major findings presented here identify the important residues in the C-terminal domain that are involved in IGF-I binding: glycine 203 and glutamine 209. Mutagenesis of both of these amino acids in the C-Term mutant has led to a cumulative effect over the single mutations reported previously (23) , with either a 30-or 10-fold reduction in the affinity of C-Term for IGF-I when measured by either solution phase assays or biosensor analysis respectively. It is possible, of course, that other residues in the C-terminal domain of IGFBP-5 may contribute to IGF-I binding. However, it is interesting to compare our findings with the biosensor analyses of Carrick et al. (11) , where they measured the IGF-I binding affinity of recombinant fragments of bovine IGFBP-2. Relative to full-length IGFBP-2, they observed a 5-fold reduction in IGF-I binding with their 1-185 fragment, which contains the entire N-terminal and central domains. This is very close to the 4.5-fold reduction in affinity for IGF-I that we observe for our C-Term 2 mutant relative to wt IGFBP-2, as derived from Scatchard analysis. Therefore, relative to the native proteins, the removal of the entire C-terminal domain in IGFBP-2 leads to a reduction in IGF-I binding very similar to that observed for both our C-Term and C-Term 2 mutants, which only carry substitutions of the C-terminal residues Gly 203 and Gln 209 or residues Gly 211 and Gln 217 in IGFBP-5 or -2, respectively. This would imply that these two amino acids are the major, if not the only, residues in the C terminus of both IGFBP-5 and -2 that are involved in IGF-I binding. The fact that they are also highly conserved throughout the IGFBP family ( Fig. 1) would also suggest that these residues are specifically involved in binding IGF-I in all six IGFBP proteins.
In this respect, it is important to remember that Gly 203 and Gln 209 lie within a major heparin-binding site in both IGFBP-5 and -3, which has previously been shown to be involved in binding to heparin and to components of the extracellular matrix (18, 19) . Although the work described above clearly indicates a role for Gly 203 and Gln 209 in binding IGF-I, we also demonstrate that these two amino acids play no part in heparin binding because heparin-ligand analysis demonstrates similar activities for wt IGFBP-5 and C-Term. Therefore, it would appear that within the C terminus of IGFBP-5, and likely also within IGFBP-3, there is an overlap of residues involved in IGF-I and heparin binding. Furthermore, because Gly 203 and Gln 209 are conserved in all six binding proteins, whereas the heparin-binding site is only common to IGFBP-5 and -3, this must mean that the IGF-I binding function of this region predates heparin binding during evolution. Taken together, this has important implications for the biological actions of these two IGFBPs, because it implies that any of the numerous functions ascribed to this region (amino acids 201-218 in IG-FBP-5) may be mutually exclusive to effective IGF-I binding. Other functions ascribed to this region in IGFBP-5 include binding to the acid labile subunit, the putative IGFBP-5 receptor, and plasminogen activator inhibitor-I, in addition to acting as a nuclear localization signal (reviewed recently in Ref. 34 ). In support of this hypothesis, others have clearly demonstrated that incubation of IGFBP-5 with heparin resulted in a 17-fold decrease in the affinity for IGF-I (35). This lowering of IGF-I affinity when the 201-218 region is otherwise occupied may be critical in obtaining the correct balance between free and bound growth factor.
Our site-directed mutagenesis strategy has also enabled us to determine the differential contributions of the N-and Cterminal domains of IGFBP-5 in binding IGF-I. Independent of the technique used to measure IGF-I binding, it is clear that the amino acid substitutions in the N-terminal domain have led to a significantly greater reduction in IGF-I binding, which would argue that the major IGF-binding site is in this domain. Nevertheless, we note that Gly 203 and Gln 209 in the C terminus also make a significant contribution to IGF-I binding. Another advantage of our site-directed mutagenesis approach over analysis of N-and C-terminal IGFBP fragments is that we were able to combine the mutations in both termini by making the NϩC-Term mutant. This clearly demonstrates that the disruption of IGF-I-binding sequences in both the N and C termini simultaneously has a cumulative effect and leads to a far greater (126-fold) reduction in IGF-I binding as measured by biosensor analysis.
Study of the individual K on and K off values from the biosensor analysis allows us to observe that the N-Term has a considerably slower association rate than C-Term (17-and 2.6-fold slower than wt IGFBP-5, respectively). However, the N-and C-Term mutants have comparable increases in dissociation rates, (both have ϳ3.5-fold faster dissociation rates than wt IGFBP-5). The effect of combining the mutations, as is the case with the NϩC-Term mutant, appears to be more pronounced on the dissociation rate (which is now 7-fold faster relative to wt IGFBP-5). Thus, there would appear to be an additive effect of the N-and C-term mutations on dissociation. Taken together, these biosensor results would suggest that although the Nterminal sequences play a major role in the association of IGF-I with IGFBP-5, the C-terminal sequences are more involved in stabilization of the IGFBP/IGF complex, because mutating these sequences increases the speed of dissociation.
In conclusion, we have identified Gly 203 and Gln 209 as the important residues in the C-terminal domain of IGFBP-5 that are involved in IGF-I binding. Although their substitution leads to a significant loss of ligand binding, it is less than that observed when several residues in the major IGF-binding site in the N-terminal domain are mutated. Further advances in this area will require the determination of the three-dimensional structure of the IGF-IGFBP complex by x-ray crystallography.
